Help Desk
860-305-6955
About PPLadmin
This author has not yet filled in any details.So far PPLadmin has created 11 blog entries.
Lilly Joins the Push for Non-Opioid Painkillers
PPLadmin2020-12-10T19:32:22+00:00In Pharma Lilly joins the push for non-opioid painkillers 03-Jun-2019 By Maggie Lynch Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement. HTTPS://WWW.IN-PHARMATECHNOLOGIST.COM/ARTICLE/2019/06/03/ELI-LILLY-LICENSES-NON-OPIOID-TREATMENT-FOR-47.5M
Phoenix PharmaLabs Celebrates Successful Netcapital Equity Offering for Non-Addictive Opioid Pain Treatment
PPLadmin2020-12-10T19:33:52+00:00Crowdfund Insider Global Banking & Finance Review Biospace
Pain Medicine is Evolving – A Non-Addictive Opioid?
PPLadmin2020-12-10T19:38:27+00:00A non-addictive opioid under development by Phoenix PharmaLabs (Utah), PPL-103, has demonstrated the potential to be a treatment for opioid, as well as cocaine, addictions, as published in a poster by Lawrence Toll, PhD, professor of biomedical science at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and chief neuropharmacologist of Phoenix [...]
How to fight drug addiction: the shift to prescription drugs
PPLadmin2020-12-10T19:42:00+00:00Full Article
In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential
PPLadmin2020-12-10T19:45:37+00:00Full Article
One Stepfather’s Quest: The Search For An Opioid That Won’t Lead To Addiction
PPLadmin2020-12-10T19:50:44+00:00Full Article
Phoenix PharmaLabs Exec Describes Novel Non-Addictive Opioid
PPLadmin2020-12-10T20:01:02+00:00Full Article
Research Declares Phoenix PharmaLabs’ Opioid PPL-103 Safe
PPLadmin2020-12-10T19:56:57+00:00Full Article
Phoenix Pharma Labs Technology Transfer Grant
PPLadmin2021-01-19T18:22:11+00:00Phoenix PharmaLabs has received a Technology Transfer Grant from the National Institutes of Health to evaluate its lead compound as a potential treatment for cocaine addiction. Dr. Larry Toll, our CTO, was recruited earlier this year by Florida Atlantic University to become the University's first recruit under the 21st Century World Class Scholars [...]